Canada - English - Health Canada

teva canada limited - salbutamol (salbutamol sulfate) - solution - 0.5mg - salbutamol (salbutamol sulfate) 0.5mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

teva canada limited - salbutamol (salbutamol sulfate) - solution - 2mg - salbutamol (salbutamol sulfate) 2mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

pharmel inc - salbutamol (salbutamol sulfate) - solution - 0.4mg - salbutamol (salbutamol sulfate) 0.4mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

ivax pharmaceuticals incorporated - salbutamol (salbutamol sulfate) - solution - 1mg - salbutamol (salbutamol sulfate) 1mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

ivax pharmaceuticals incorporated - salbutamol (salbutamol sulfate) - solution - 2mg - salbutamol (salbutamol sulfate) 2mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

teva canada limited - salbutamol (salbutamol sulfate) - metered-dose aerosol - 100mcg - salbutamol (salbutamol sulfate) 100mcg - selective beta 2-adrenergic agonists

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss);   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss)   excipient: norflurane - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage);   - solution for inhalation - 2.5mg/2.5ml - active: salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage);   - solution for inhalation - 5mg/2.5ml - active: salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - salbutamol sulfate -